The High‐Sensitivity C‐Reactive Protein−Albumin−Lymphocyte Index Is a Prognostic Marker for All‐Cause and Cardiovascular Mortality in Patients With ST‐Elevation Myocardial Infarction
Catheterization and Cardiovascular Interventions · 2026
DOI: 10.1002/ccd.70745 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2026. Verfasst von Xinuo Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China. Hauptthemen laut MEDLINE: ST Elevation Myocardial Infarction, C-Reactive Protein, Percutaneous Coronary Intervention, Lymphocytes. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Applied Basic Research Program of the Yunnan Province Science and Technology Department and Kunming Medical University.
Abstract (Originalsprache)
Background
Inflammation and immune dysfunction may worsen the prognosis of patients with ST‐segment elevation myocardial infarction (STEMI).
Aims
This study aimed to assess whether the high‐sensitivity C‐reactive protein–albumin–lymphocyte index (hsCALLYI) could be used to predict the prognosis of STEMI patients who received emergency percutaneous coronary intervention (PCI) treatment.
Methods
Participants were categorized into three groups based on hsCALLYI tertiles. To assess the prognostic significance of hsCALLYI in predicting both all‐cause and cardiovascular mortality, Kaplan–Meier survival curves were constructed, followed by Cox proportional hazards regression modeling and time‐dependent receiver operating characteristic (ROC) curve analysis.
Results
A lower level of hsCALLYI demonstrated a significant correlation with elevated mortality risk from all causes (hazard ratio [HR] = 9.826, 95% CI = 3.091–31.235, p < 0.001) and cardiovascular mortality (HR = 15.035, 95% CI = 3.353–67.408, p < 0.001). The area under the ROC curve of hsCALLYI for all‐cause mortality was 0.696 ( p < 0.05), and the area under the ROC curve of hsCALLYI for cardiovascular mortality was 0.695 ( p < 0.05). Conclusion hsCALLYI emerged as a significant independent prognostic indicator for both all‐cause and cardiovascular mortality in STEMI patients undergoing emergency PCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
- Department of Emergency Medicine, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
- Anesthesiology department, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
- Department of Pediatrics, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Förderung
- Applied Basic Research Program of the Yunnan Province Science and Technology Department and Kunming Medical University
Zitieren
APA
Ma, X., Zhang, W., Zhang, N., Zhong, Q., Shi, T., Yang, S., Yang, F., Peng, Y., & Chen, L. (2026). The High‐Sensitivity C‐Reactive Protein−Albumin−Lymphocyte Index Is a Prognostic Marker for All‐Cause and Cardiovascular Mortality in Patients With ST‐Elevation Myocardial Infarction. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70745
Vancouver
Ma X, Zhang W, Zhang N, Zhong Q, Shi T, Yang S, et al. The High‐Sensitivity C‐Reactive Protein−Albumin−Lymphocyte Index Is a Prognostic Marker for All‐Cause and Cardiovascular Mortality in Patients With ST‐Elevation Myocardial Infarction. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70745
BibTeX
@article{Ma2026,
author = {Ma, Xinuo and Zhang, Wei and Zhang, Ningli and Zhong, Qinghua and Shi, Tao and Yang, Sirui and Yang, Fazhi and Peng, Yujuan and Chen, Lixing},
title = {The High‐Sensitivity C‐Reactive Protein−Albumin−Lymphocyte Index Is a Prognostic Marker for All‐Cause and Cardiovascular Mortality in Patients With ST‐Elevation Myocardial Infarction},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
doi = {10.1002/ccd.70745}
}
EUVIMED